Quantcast
Last updated on April 23, 2014 at 1:22 EDT

International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia

June 14, 2012

AMSTERDAM, June 15, 2012 /PRNewswire/ –

“There is a large potential opportunity for saving lives by early identification of
cardiac iron loading in Thalassemia patients”, declares Professor John-Paul Carpenter of
the Royal Brompton CMR Unit in London at the 17th Congress of the European Hematology
Association in Amsterdam.

Thalassemia major (TM) is a substantial health issue, with over 25,000 new
transfusion-dependent children identified each year around the world. In most TM patients
who receive regular transfusions, the accumulation of cardiac iron is the cause of heart
failure and early death. T2* cardiovascular magnetic resonance (CMR) provides a calibrated
and reproducible measurement of myocardial iron which has contributed to improved survival
in TM patients. However, there is little data regarding myocardial iron loading and its
relation to outcome across the world.

We report a survey of 3,411 patients in 34 centres which use T2* CMR. Even in this
cohort of well-treated TM patients from across the world which had access to regular
transfusion, chelation and T2* CMR, a large proportion (42.3%) had moderate or severe
myocardial iron loading. There were substantial regional differences in the prevalence of
cardiac iron overload which, despite differences in clinical care, may indicate varying
predisposition to myocardial iron loading. T2* CMR identified those patients at increased
risk with myocardial T2* values <10ms being strongly associated with the future
development of cardiac failure and death. There is a large potential opportunity for
saving lives by early identification of cardiac iron loading and T2* CMR needs to be more
widely available.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress
of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to
do with blood: its origin in the bone marrow, diseases (in the production) of blood and
their treatments. The latest data on research and developments within the wide spectrum of
hematology are presented.

SOURCE European Hematology Association


Source: PR Newswire